A important advancement in diabetes care is emerging with the approval of tirzepatide at a dosage of 45mg. This new formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 receptor, and https://apollobookmarks.com/story21252362/significant-approach-tirzepatide-strength-for-diabetes-control